Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
· disc medicine inc
AI Briefing
- Disc Medicine completes enrollment in Phase 3 APOLLO trial of bitopertin for Erythropoietic Protoporphyria
- Study expanded from N=150 to N=183 due to strong demand
- Company focused on development of novel treatments for hematologic diseases
Advertisement